Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10413246 | 0.98 | CHEK1 (0.39) | CHEK1SLC6A2SLC6A4ALDH1A1POLB | |
| SCHEMBL14506021 | 0.85 | ALDH1A1 (0.38) | CHEK1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL28302157 | 0.84 | CHEK1 (0.39) | CHEK1SLC6A2SLC6A4CHEK2SSTR4 | |
| SCHEMBL734651 | 0.80 | CHEK1 (0.45) | CHEK1SLC6A2SLC6A4SMN1; SMN2MEN1 | |
| SCHEMBL4146870 | 0.80 | CHEK1 (0.45) | CHEK1SLC6A2SLC6A4SMN1; SMN2MEN1 | |
| SCHEMBL22776149 | 0.80 | CHEK1 (0.45) | CHEK1SLC6A2SLC6A4SMN1; SMN2MEN1 | |
| SCHEMBL14690710 | 0.80 | SMN1; SMN2 (0.46) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1501987 | 0.79 | SLC6A2 (0.51) | CHEK1SLC6A2SLC6A4SMN1; SMN2CHEK2 | |
| Hydrochloric Acid SCHEMBL19692370 | 0.79 | CHEK1 (0.44) | CHEK1SLC6A2SLC6A4SMN1; SMN2MEN1 | |
| SCHEMBL17866282 | 0.79 | CHEK1 (0.49) | CHEK1SLC6A2SLC6A4SMN1; SMN2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7560548-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7531651-B2 | Benzenesulphonate salt of a morpholine urea derivative for use as a CCR-3 antagonist in the treatment of inflammatory conditions | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-7531651-B2 | Benzenesulphonate salt of a morpholine urea derivative for use as a CCR-3 antagonist in the treatment of inflammatory conditions | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2003082295-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY A HETEROCYCLYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082293-A1 | BENZENESULPHONATE SALT OF A MORPHOLINE UREA DERIVATIVE FOR USE AS A CCR-3 ANTAGONIST IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082292-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082834-A2 | MORPHOLINE DERIVATIVES AND INTERMEDIATES THEREFOR | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-1324991-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ARG1, ARG2, NFKBIA | CHEK1 4801/4885SLC6A2 4280/4885SLC6A4 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.